Last updated: May 24, 2026
H1: Varithena Suppliers and Contract Manufacturers for Polidocanol Injection
Who manufactures Varithena polidocanol injection?
Varithena is marketed in the U.S. by AbbVie (through Allergan historically). Production is typically executed through a combination of internal manufacturing and third-party sterile-injection contract manufacturing, depending on batch demand and regulatory status of manufacturing sites.
What does the supply chain usually include?
Varithena supply is commonly structured around:
- Polidocanol drug substance manufacturing (chemical synthesis and purification).
- Finished-dose manufacturing (sterile manufacturing operations, including bulk drug product handling).
- Sterile fill-finish (aseptic filling, stopper/capping systems, and inspection).
- Final packaging (cartoning, labeling, unit-of-use presentation).
What companies supply the active ingredient (polidocanol) for Varithena?
Polidocanol is a niche injectable local anesthetic/sclerosant active ingredient used across multiple vascular indications. Supplier ecosystems for polidocanol injection drugs typically include specialized chemical manufacturers capable of meeting injectable-grade specifications (identity, purity, residual solvents, and endotoxin/bioburden controls where applicable).
Direct “named supplier” attribution for Varithena’s specific polidocanol manufacturer is typically tracked in:
- FDA manufacturing site information tied to the NDA/BLA drug product and manufacturing facilities.
- Label manufacturing sections listing “Manufactured for” and “Distributed by” parties.
- Regulatory submissions for site changes or supplements (CMC filings).
Which contract manufacturers (CMOs) produce Varithena injection?
CMOs for sterile injectable products are generally selected from firms with:
- Aseptic processing and environmental monitoring capabilities.
- Validation for container closure integrity (CCI).
- Lyophilization and/or sterile solution fill-finish (depending on the commercial presentation).
- Ongoing cGMP compliance history with comparable sterile injection lines.
For Varithena specifically, identification of the contract manufacturers depends on the labeled manufacturing sites and the FDA facility listings for the approved application.
What does the Orange Book list for Varithena that impacts suppliers?
Orange Book data for small-molecule injectables often drives supplier decisions because it anchors:
- Legal status of formulation, method-of-use, and manufacturing/process patents tied to the drug substance and drug product.
- Which dosage forms are covered (directly impacting which line(s) a CMO can support).
- Whether a generic pathway is tied to the same manufacturing process or different manufacturing descriptions.
Supplier selection is tied to formulation/process control parameters when patents and regulatory comparability are in play.
When do Varithena patent and exclusivity events affect supply sourcing?
Supply chain planning is typically tied to:
- Patent expiration timing for formulation and method-of-use coverage.
- Potential Paragraph IV challenges and subsequent litigation that can constrain alternative sourcing.
- CMO capacity planning around anticipated demand shifts as exclusivity weakens.
Operationally, manufacturers and CMOs increase inventory or secure second-line capacity before key exclusivity or patent cliff events.
How do Paragraph IV or litigation risks affect Varithena supply contracts?
If generic or biosimilar-adjacent entries are filed, brand owners commonly:
- Tighten control over raw materials and packaging components tied to the protected presentation.
- Add secondary CMOs or second-line sterile capacity to avoid shortages.
- Negotiate longer lead-time schedules for critical components (fill needles, stoppers, syringes, labels).
The supplier impact is most pronounced for sterile fill-finish constraints and for long-lead packaging items.
What dosage forms and presentation details determine which suppliers can support Varithena?
Varithena’s clinical use requires specific device and container closure compatibility. Supplier eligibility usually hinges on:
- Container closure system specifications (stopper materials, syringe types, or vial systems).
- Sterility assurance method compatibility.
- Visual inspection and particulate specs.
- Labeling format and traceability requirements.
How does AbbVie’s Varithena supply strategy typically structure sourcing?
For specialty injectables, supply strategies are commonly:
- Primary production at labeled manufacturing sites (internal or preferred CMOs).
- Backup manufacturing at second qualified sterile CMOs.
- Dedicated supply of constrained packaging components.
This approach reduces risk of supply interruptions from site downtime, regulatory holds, or component shortages.
What manufacturing/IP barriers can limit alternative suppliers for Varithena?
Alternative suppliers face constraints beyond cGMP:
- Protected manufacturing process claims (where claimed).
- Formulation and method-of-use patent coverage that can require specific product characteristics.
- Regulatory comparability expectations tied to particle size, concentration, pH range, and stability.
If a CMO cannot replicate the full control strategy, the company may be blocked from offering a regulatory-ready product.
Key supplier landscape for Varithena: how to benchmark
A practical supplier benchmark for Varithena-like products uses these filters:
- Sterile injectable capacity (aseptic filling, environmental monitoring, batch release timelines).
- Injectable container closure systems and CCI testing competence.
- Proven track record with polidocanol or comparable sclerosant formulations (where available).
- Ability to support long-term supply with validated component supply.
- Regulatory inspection history for sterile facility operations.
Key Takeaways
- Varithena supply is anchored by AbbVie (historically Allergan) as the marketer, with manufacturing performed through labeled facilities and qualified CMOs for sterile injection fill-finish.
- Polidocanol drug substance supply requires injectable-grade chemical manufacturing capability.
- Sterile fill-finish and container closure compatibility are the key determinants of which suppliers can support Varithena.
- Patent and litigation timelines shape inventory and backup CMO contracting around demand and exclusivity transitions.
FAQs
- How can I identify the specific FDA-listed manufacturing sites for Varithena drug product?
- Which sterile fill-finish capabilities are required to manufacture polidocanol injection products like Varithena?
- What criteria do polidocanol drug substance suppliers need to meet for injectable-grade products?
- How do back-up CMOs reduce supply interruption risk for specialty sterile injectables such as Varithena?
- What packaging and container closure components typically create the longest lead times for injectable products?
References (APA)
- U.S. Food and Drug Administration. (n.d.). Drug manufacturing and FDA facility information (public databases and labeling resources).
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- FDA label and approval documentation for Varithena (polidocanol injection) (public prescribing information and application records).
